Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment practices and lipid profile of patients with acute coronary syndrome: results from a tertiary care hospital.
Farmakis I, Zafeiropoulos S, Kartas A, Boulmpou A, Nevras V, Papadimitriou I, Tampaki A, Vlachou A, Markidis E, Koutsakis A, Ziakas A, Karvounis H, Giannakoulas G. Farmakis I, et al. Among authors: papadimitriou i. Acta Cardiol. 2020 Oct;75(6):527-534. doi: 10.1080/00015385.2019.1626087. Epub 2019 Jun 20. Acta Cardiol. 2020. PMID: 31219734 Clinical Trial.
Motivational interviewing to support LDL-C therapeutic goals and lipid-lowering therapy compliance in patients with acute coronary syndromes (IDEAL-LDL) study: rationale and design.
Boulmpou A, Kartas A, Farmakis I, Zafeiropoulos S, Nevras V, Papadimitriou I, Tampaki A, Vlachou A, Lillis L, Koutsakis A, Karvounis H, Giannakoulas G. Boulmpou A, et al. Among authors: papadimitriou i. Hellenic J Cardiol. 2019 Jul-Aug;60(4):249-253. doi: 10.1016/j.hjc.2018.10.002. Epub 2018 Oct 21. Hellenic J Cardiol. 2019. PMID: 30352291 Free article. Clinical Trial.
Low-density lipoprotein cholesterol target value attainment based on 2019 ESC/EAS guidelines and lipid-lowering therapy titration for patients with acute coronary syndrome.
Farmakis I, Zafeiropoulos S, Pagiantza A, Boulmpou A, Arvanitaki A, Tampaki A, Kosmidis D, Nevras V, Markidis E, Papadimitriou I, Karvounis H, Giannakoulas G. Farmakis I, et al. Among authors: papadimitriou i. Eur J Prev Cardiol. 2020 Dec;27(19):2314-2317. doi: 10.1177/2047487319891780. Epub 2019 Dec 9. Eur J Prev Cardiol. 2020. PMID: 31818140 No abstract available.
Risk for Recurrent Cardiovascular Events and Expected Risk Reduction With Optimal Treatment 1 Year After an Acute Coronary Syndrome.
Zafeiropoulos S, Farmakis I, Kartas A, Arvanitaki A, Pagiantza A, Boulmpou A, Tampaki A, Kosmidis D, Nevras V, Markidis E, Papadimitriou I, Arvanitakis K, Sianos G, Makedou K, Ziakas A, Tzikas A, Karvounis H, Giannakoulas G. Zafeiropoulos S, et al. Among authors: papadimitriou i. Am J Cardiol. 2020 Oct 15;133:7-14. doi: 10.1016/j.amjcard.2020.07.046. Epub 2020 Jul 28. Am J Cardiol. 2020. PMID: 32828524
Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial.
Zafeiropoulos S, Farmakis I, Kartas A, Arvanitaki A, Pagiantza A, Boulmpou A, Tampaki A, Kosmidis D, Nevras V, Markidis E, Papadimitriou I, Vlachou A, Arvanitakis K, Miyara SJ, Ziakas A, Molmenti EP, Kassimis G, Zanos S, Karvounis H, Giannakoulas G. Zafeiropoulos S, et al. Among authors: papadimitriou i. Atherosclerosis. 2021 Apr;323:37-43. doi: 10.1016/j.atherosclerosis.2021.03.013. Epub 2021 Mar 17. Atherosclerosis. 2021. PMID: 33780749 Clinical Trial.
No association between ACTN3 R577X and ACE I/D polymorphisms and endurance running times in 698 Caucasian athletes.
Papadimitriou ID, Lockey SJ, Voisin S, Herbert AJ, Garton F, Houweling PJ, Cieszczyk P, Maciejewska-Skrendo A, Sawczuk M, Massidda M, Calò CM, Astratenkova IV, Kouvatsi A, Druzhevskaya AM, Jacques M, Ahmetov II, Stebbings GK, Heffernan S, Day SH, Erskine R, Pedlar C, Kipps C, North KN, Williams AG, Eynon N. Papadimitriou ID, et al. BMC Genomics. 2018 Jan 3;19(1):13. doi: 10.1186/s12864-017-4412-0. BMC Genomics. 2018. PMID: 29298672 Free PMC article.
The ACTN3 gene in elite Greek track and field athletes.
Papadimitriou ID, Papadopoulos C, Kouvatsi A, Triantaphyllidis C. Papadimitriou ID, et al. Int J Sports Med. 2008 Apr;29(4):352-5. doi: 10.1055/s-2007-965339. Epub 2007 Sep 18. Int J Sports Med. 2008. PMID: 17879893
ACTN3 R577X and ACE I/D gene variants influence performance in elite sprinters: a multi-cohort study.
Papadimitriou ID, Lucia A, Pitsiladis YP, Pushkarev VP, Dyatlov DA, Orekhov EF, Artioli GG, Guilherme JP, Lancha AH Jr, Ginevičienė V, Cieszczyk P, Maciejewska-Karlowska A, Sawczuk M, Muniesa CA, Kouvatsi A, Massidda M, Calò CM, Garton F, Houweling PJ, Wang G, Austin K, Druzhevskaya AM, Astratenkova IV, Ahmetov II, Bishop DJ, North KN, Eynon N. Papadimitriou ID, et al. BMC Genomics. 2016 Apr 13;17:285. doi: 10.1186/s12864-016-2462-3. BMC Genomics. 2016. PMID: 27075997 Free PMC article.
ACE I/D gene variant predicts ACE enzyme content in blood but not the ACE, UCP2, and UCP3 protein content in human skeletal muscle in the Gene SMART study.
Yan X, Dvir N, Jacques M, Cavalcante L, Papadimitriou ID, Munson F, Kuang J, Garnham A, Landen S, Li J, O'Keefe L, Tirosh O, Bishop DJ, Voisin S, Eynon N. Yan X, et al. J Appl Physiol (1985). 2018 Sep 1;125(3):923-930. doi: 10.1152/japplphysiol.00344.2018. Epub 2018 Jun 21. J Appl Physiol (1985). 2018. PMID: 29927735 Free article.
71 results